Last reviewed · How we verify
Gracevit (SITAFLOXACIN)
Gracevit (generic name: SITAFLOXACIN) is a sitafloxacin Small molecule drug developed by Daiichi Sankyo. It is currently FDA-approved for Respiratory tract infection, Urinary tract infectious disease.
Sitafloxacin is a small molecule bacterial DNA gyrase inhibitor, classified as an inhibitor. It is being studied in a clinical trial (NCT05400369) for the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | SITAFLOXACIN |
|---|---|
| Sponsor | Daiichi Sankyo |
| Drug class | sitafloxacin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Respiratory tract infection
- Urinary tract infectious disease
Common side effects
Key clinical trials
- A PAN-USR TB Multi-Center Trial (PHASE3)
- Ultra-Short Regimen for Elderly DS-TB (PHASE3)
- Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (PHASE4)
- Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients (PHASE2,PHASE3)
- Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment (PHASE3)
- Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults (PHASE4)
- Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gracevit CI brief — competitive landscape report
- Gracevit updates RSS · CI watch RSS
- Daiichi Sankyo portfolio CI
Frequently asked questions about Gracevit
What is Gracevit?
What is Gracevit used for?
Who makes Gracevit?
What is the generic name of Gracevit?
What drug class is Gracevit in?
What development phase is Gracevit in?
Related
- Drug class: All sitafloxacin drugs
- Manufacturer: Daiichi Sankyo — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Respiratory tract infection
- Indication: Drugs for Urinary tract infectious disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing